Navigating novel treatment options in nonmuscle-invasive #BladderCancer for nurses and APPs - Samantha Steinke, APRN, MSN-FNP, BSN, RN & Brenda Martone, MSN, ANP-BC, AOCNP @NorthwesternMed address coordination within the expanding NMIBC treatment landscape. Novel intravesical agents are supported by manufacturer-provided education covering side effects and administration workflows. Since some treatments require infusion capacity beyond urology's usual space, Nurse Steinke's practice has started coordinating with campus infusion teams, establishing communication pathways as adoption increases. #WatchNow > bit.ly/3T5gHie@NUFeinbergMed@LurieCancer
Restricted Mean Survival Time Analysis of First-Line IO Combinations in Advanced RCC.
How much survival do first-line IO combinations add in advanced #RCC? @yuish_uro joins @PBarataMD to discuss a restricted mean survival time analysis of 4 phase 3 trials; ipi-nivo was most cost-effective per month gained. #WatchNow > bit.ly/4jCq43I
Comparison of Aquablation with TURP in Benign Prostatic Hyperplasia.
Is aquablation the new go-to for #BPH? @dsui_miami_uro joins Alan Wein, MD, PhD(hon), FACS to compare aquablation with TURP and highlights its better preservation of ejaculatory and sexual function. #WatchNow > bit.ly/4jXB37Z
Intravesical Gentamicin Instillations for Recurrent Urinary Tract Infections.
Recurrent #UTI in neurogenic bladder: Anne Pelletier Cameron, MD, FRCSC, URPS @UMich joins Alan J. Wein, MD, PhD(hon), FACS @dsui_miami_uro to discuss intravesical gentamicin, which cut lab-proven symptomatic UTIs from 3.9 to 1.1 per year. #WatchNow on UroToday > bit.ly/4jWfYuA
ROBUST III Trial Results in Short Bulbar Urethral Strictures.
3-year ROBUST III results for recurrent #UrethralStricture: Sean Elliott, MD @UMNews joins Alan Wein, MD, PhD(hon), FACS @dsui_miami_uro to discuss the drug-coated balloon, with 71.9% of men free from repeat intervention at 3 years. #WatchNow on UroToday > bit.ly/3W8xH8e
Proactive adverse event management for talazoparib plus enzalutamide in metastatic APMS. @CaPsurvivorship@DanaFarber joins @neerajaiims@huntsmancancer to discuss anemia management in the TALAPRO-3 regimen. The trial added talazoparib to enzalutamide in HRR-mutated metastatic hormone-sensitive prostate cancer, achieving 52% rPFS risk reduction. Dr. Morgans recommends an anemia panel at baseline to identify correctable causes before attributing low hemoglobin to treatment. #WatchNow > bit.ly/45AOzWS
Dose-Intensified PSMA Radioligand Therapy: The Rationale Behind the OPTIMAL-PSMA Trial
Can dose intensification improve PSMA radioligand therapy in #mCRPC? The rationale behind OPTIMAL-PSMA, a randomized phase 2 trial of dose-intensified 177Lu-PSMA. #AuthorCommentary with Sobia Khan, Gemma Sheehan-Dare, and @drlouiseemmett > bit.ly/4dVAxDJ
Practical management of nonmuscle-invasive #BladderCancer treatment in the clinic. Samantha Steinke, APRN, MSN-FNP, BSN, RN & Brenda Martone, MSN, ANP-BC, AOCNP @NorthwesternMed review practical intravesical BCG administration. Therapy uses a Foley catheter with a two-hour dwell time, administered either at home or in the clinic based on patient preference and travel distance. Common self-limited side effects, such as urinary frequency, urgency, and low-grade fever, generally appear by treatment three or four, with onset delayed until later that day and typically resolving within 48 hours. #WatchNow > bit.ly/3UVFdmp@NUFeinbergMed@LurieCancer#NMIBC
A Catheter-Free Bladder Sensor for Natural Voiding Urodynamics.
Catheter-free #urodynamics: @Jason_Kim_MD@SBUrology joins Alan Wein, MD, PhD(hon), FACS, @dsui_miami_uro to discuss a wireless bladder sensor for natural-voiding testing. Setup takes about 20–30 minutes vs 60–90 minutes for conventional urodynamics. #WatchNow > bit.ly/4i9ceDy
SBRT in Oligometastatic Castrate-Resistant #ProstateCancer.
Where does SBRT fit in oligometastatic #CRPC? @ZilliThomas joins @l_ballas to review the evidence. He notes that in PCS 9, adding SBRT to enzalutamide extended radiographic PFS from 2 to 4.6 years. #WatchNow > bit.ly/4zb8fhg
The Future of Urodynamic Evaluation in Male Lower Urinary Tract Dysfunction.
Where is #LUTS diagnostics headed? Bradley Gill, MD, MS @ClevelandClinic joins Alan Wein, MD, PhD(hon), FACS @dsui_miami_uro to discuss urodynamic evaluation of male lower urinary tract dysfunction, from current practice to emerging tools and technologies. #WatchNow > bit.ly/4sjoDcO
Identifying the right patient for lutetium-177-PSMA-617 in #mHSPC. @DrScottTagawa@WeillCornell joins @CaPsurvivorship@DanaFarber to discuss patient selection for lutetium-177-PSMA-617 in the PSMAddition setting. Entry required metastatic disease on CT or bone scan, PSMA-positive PET, adequate organ function, and fitness for ADT plus ARPI without chemotherapy. #WatchNow > bit.ly/4x6yMuP